NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Thanks Lykiri, it’s also very impressive that NWBio / Advent was able to make 22 DCVax-L vaccine doses for this patient (Charles Nap) from his resected tumor.

That means, based on the prescribed dosing regimen for DCVax-L (6 shots the first year, and then 2 shots each year thereafter), they were able to make DCVax-L dosages to cover 9 full years of treatment:



https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6

That would be 6 shots the first year, with 16 doses remaining (22 - 6 = 16 ). Then the 16 shots remaining, at 2 maintenance DCVax—L shots per year thereafter would last an additional 8 years, for a total of 9 years of DCVax-L vaccine treatments.

That makes it laughable when detractors say stupid things like “DCVax-L is too expensive or cost too much at $250,000 (about £200,000) and will not be appraised by NICE to be covered by the NHS national insurance in the U.K.

When you take $250,000 for the total cost of 9 years of DCVax-L treatment, then the treatment cost would be about $27,778 per year ($250,000 / 9 years), of $11,363 per dose ($250,000 / 22).

The truth is, DCVax-L is very cheap compared to other cell therapies and gene therapies. Even though, all solid tumor cancer patients will not have enough tumor resected to produce 9 or 10 years of doses, even at 3 years or 5 years of doses, the cost of DCVax-L is very affordable.